PD-1 involvement in CD8 + tumor-infiltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma

Sep 23, 2026

Uploaded by James

Immune checkpoint blockade with anti-PD-1 antibody is explored for human malignancies, focusing on whether the proportion of PD-1 in CD8+ tumor-infiltrating lymphocytes relates to progression of colonic-derived peritoneal adenocarcinoma (PA). Peripheral blood and tissue samples from 40 PA patients were analyzed by multicolor flow cytometry for peripheral PD-1+CD8+ T cells, and by multiple immunofluorescence to quantify PD-1 and CD8 positivity in tissues. PD-1+, CD8+, and PD-1+CD8+ cells were more abundant in paracancer tissue than in cancer tissue. PD-1+CD8+ T cells showed higher levels in peripheral blood than in tissues and were elevated in patients with shorter recurrence intervals. The tissue level of PD-1+CD8+ T cells correlated with clinical outcomes, and higher proportions were associated with shorter progression-free survival (PFS), suggesting prognostic and predictive value for immunotherapy.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Abstract

Introduction

Immune checkpoint blockade and PD-1 background

PD-1 exhaustion and clinical correlations

Study purpose

Brazilian Journal of Medical and Biological Research (2025) 58: e14467, [https://doi.org/10.1590/1414-431X2025e14467](https://doi.org/10.1590/1414-431X2025e14467) ISSN 1414-431X Research Article 1/7 PD-1 involvement in CD8 + tumor-inﬁltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma Huihui Hu 1 00 and Man Zhang 1,2,3 00 1Department of Clinical Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 2Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China 3Clinical Laboratory Medicine, Peking University Ninth School of Clinical Medicine, Beijing, China Abstract Immune checkpoint blockade with anti-programmed cell death protein 1 (PD-1) antibody has become a hot topic for the treatment of human malignancies. Here, we aimed to investigate whether the percentage of PD-1 in CD8 + tumor-inﬁltrating lymphocytes correlates with the progression of colonic-derived peritoneal adenocarcinoma (PA) . Peripheral blood and tissue samples from 40 patients with colonic-derived PA were collected and subjected to multicolor ﬂow cytometry analysis of the percentage of peripheral PD-1 +CD8+ T cells. The multiple immunoﬂuorescence method was used to detect the positive percentages of PD-1 and CD8 in the tissues. The enrolled patients were divided into groups by recurrence interval (less than 6 months, greater than two years) and differentiation grade (low, well/moderate) . In the colonic-derived PA tissues, the percentages of cells positive for PD-1, CD8, and PD-1 +CD8+ were higher in the paracancer tissues compared with cancerous tissues. PD-1 +CD8+ T cells had an increased presence in peripheral blood than in tissues. Our data also indicated that colonic-derived PA patients with less than a six-month recurrence interval presented higher levels of PD-1 in CD8 + tumorinﬁltrating lymphocytes in than the two-year recurrence group. The level of PD-1 +CD8+T cells in the tissue correlated with the clinical outcome of colonic-derived PA. Higher percentages of PD-1 +CD8+T cells correlated with a shorter progression-free survival (PFS) . PD-1 in CD8 + tumor-inﬁltrating lymphocytes may have a good predictive value for immunotherapy of colonicderived PA and act as the prognostic factor for PFS. Key words: PD-1; CD8; Colonic-derived peritoneal adenocarcinoma; Recurrence; Flow cytometry; Multiple immunoﬂuorescences Introduction Colonic-derived peritoneal adenocarcinoma (PA) is the most common pathologic type of peritoneal tumor. Due to the insidious onset and relatively difﬁcult treatment of this disease, it is crucial to ﬁnd an effective clinical treatment (1) . Most PAs are metastatic, and colon cancer is the most common primary lesion. The most prominent features of colonic-derived PA are diffused or localized invasive malignancy. Although clinical therapy for the colonicderived PA in recent years has become multi-modal, most patients do not experience clinical beneﬁts after undergoing radical resection and chemotherapy. Immune checkpoint blockade was an innovation in cancer treatment (2–4) . Although immune checkpoint therapy has achieved good remission in some cancer patients, there are few reports on its use in colonic-derived PA. Programmed cell death protein 1 (PD-1) is part of the B7/CD28 family and is mainly expressed by activated T cells. It acts as a key immune-checkpoint receptor in the regulation of immunosuppression (5,6) . Immunotherapy is now considered to be the key treatment for cancer, and the PD-1 checkpoint has achieved signiﬁcant progress in clinical therapy for human melanoma, lung cancer, renal cancer, and Hodgkin ’s lymphoma (7) . Immune checkpoints expressed by T cells can negatively mediate human immunity against tumors. Lymphocyte subsets are important tools for revealing the immune status of the human body (8) . More recent studies in immunotherapy have further demonstrated the synergistic effect on tumor immune response acti

FAQs

What was the main goal of the study on PD-1 and CD8+ tumor-infiltrating lymphocytes?

To determine whether the proportion of PD-1 in CD8+ tumor-infiltrating lymphocytes is associated with progression of colonic-derived peritoneal adenocarcinoma (PA).

How were PD-1 and CD8+ T cells measured in patients?

Peripheral blood PD-1+CD8+ T cells were assessed using multicolor flow cytometry, and tissue PD-1 and CD8 positivity were evaluated using multiple immunofluorescence.

What relationship was found between PD-1+CD8+ T cells and clinical outcomes?

Higher tissue levels of PD-1+CD8+ T cells correlated with worse outcomes and shorter progression-free survival (PFS).

Sep 23, 2026

Uploaded by James